CYCN - Company ID 0001755237
Cyclerion Therapeutics, Inc. trades as CYCN. In its fiscal 2025 annual report the company posted revenue of $2.07M, up 3.7% from the prior year and net income of -$3.53M. This page tracks Cyclerion Therapeutics, Inc. through 344 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 6 fiscal years Cyclerion Therapeutics, Inc.'s revenue declined from $4.51M to $2.07M, a compound annual decline rate of 12.1%. Net profit margin expanded from -2729.3% to -170.1% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-12 |
| SCHEDULE 13G | - | 2026-05-07 |
| Annual report (amended) | 10-K/A | 2026-04-30 |
| S-4 | - | 2026-04-20 |
| 425 | - | 2026-04-01 |
| Major company event | 8-K | 2026-04-01 |
| Annual report | 10-K | 2026-03-30 |
| Major company event | 8-K | 2026-02-17 |
The largest companies sharing Cyclerion Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Cyclerion Therapeutics, Inc. reported revenue of $2.07M for fiscal year 2025, an increase of 3.7% year over year.
In its latest fiscal year Cyclerion Therapeutics, Inc. reported a net loss of $3.53M.